Tamoxifen is being evaluated in clinical trials as a preventive agent in women at high risk for breast cancer. This new, potentially long-term therapeutic role has generated some concerns regarding safety, based on the results of
James A. Swenberg, DMV, PhD
Advertisement
Articles by James A. Swenberg, DMV, PhD
Advertisement
Latest Updated Articles
- Clinical Relevance of Laboratory and Animal Data on Tamoxifen
Published: February 1st 1997 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma
2
How ADCs are Replacing Chemotherapy as Breast Cancer Treatment
3
What Were The Most Impactful GU Oncology Data From ESMO 2025?
4
Daratumumab Approval May Be “Game Changer” in High-Risk Smoldering Myeloma
5
